{"id":9458,"date":"2020-06-02T17:55:48","date_gmt":"2020-06-02T12:25:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9458"},"modified":"2023-02-10T11:46:02","modified_gmt":"2023-02-10T06:16:02","slug":"recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","title":{"rendered":"Eli Lilly&#8217;s COVID-19 Antibody trial; Approval for Oriahnn; Gilead&#8217;s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f9638524c1a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f9638524c1a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\/#Eli_Lilly_and_AbCellera_announced_the_dosing_of_the_patients_suffering_from_COVID-19_with_antibody_candidate_%E2%80%93_LY-CoV555\" >Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate &#8211; LY-CoV555.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\/#AbbVie_has_received_the_recommendation_for_its_oral_treatment_Oriahnn_to_treat_heavy_menstrual_bleeding_due_to_uterine_fibroids\" >AbbVie has received the recommendation for its oral treatment Oriahnn to treat heavy menstrual bleeding due to uterine fibroids.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\/#Gilead_Sciences_reported_the_results_of_a_Phase_III_trial_study_evaluating_the_efficacy_and_safety_of_Remdesivir_in_moderate_COVID-19_patients\" >Gilead Sciences reported the results of a Phase III trial study evaluating the efficacy and safety of Remdesivir in moderate COVID-19 patients.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\/#Russias_Ministry_of_Health_gave_an_emergency_use_approval_for_Avifavir_to_fight_SARS-CoV-2_infections\" >Russia\u2019s Ministry of Health gave an emergency use approval for Avifavir to fight SARS-CoV-2 infections.<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-and-abcellera-announced-the-dosing-of-the-patients-suffering-from-covid-19-with-antibody-candidate-ly-cov555\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_and_AbCellera_announced_the_dosing_of_the_patients_suffering_from_COVID-19_with_antibody_candidate_%E2%80%93_LY-CoV555\"><\/span><strong>Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate &#8211; LY-CoV555.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft is-resized\"><img decoding=\"async\" src=\"https:\/\/lh6.googleusercontent.com\/PnNx4-iycHr-TtR_YMmI30bAnRTxnK1PqeNkDmTm5trfxSCFooz113anoRou4SjnWjBGB-HYQ1p8K8feKLTflwbVOX4FVe9_-F1pa6jvhlkfyQuRcNK3GxTJ6aBQPaNiXVpt8U7G1ZeSkaAZ8A\" alt=\"Lilly-abcellera\" width=\"173\" height=\"93\"\/><\/figure><\/div>\n\n\n<p> LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> has taken the lives of more than 372,000 people globally.&nbsp;<\/p>\n\n\n\n<p>The antibody was developed by Lilly after the successful identification of it through the AbCellera\u2019s rapid artificial intelligence-based pandemic response platform from one of the US patients who managed to recover from the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID<\/strong><\/a>.<\/p>\n\n\n\n<p>The antibody blocks the entry and linking of the viral particles to human cells and prevents the disease. Since the antibody is derived from the blood of a recovered patient, the company claims it to be the potential new medicine specifically designed to attack <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\"><strong>SARS-CoV-2<\/strong><\/a>.&nbsp;<\/p>\n\n\n\n<p>Moreover, Lilly is planning to test the antibody along with several others, as a monotherapy as well as in combinations, in the coming next months.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-has-received-the-recommendation-for-its-oral-treatment-oriahnn-to-treat-heavy-menstrual-bleeding-due-to-uterine-fibroids\"><span class=\"ez-toc-section\" id=\"AbbVie_has_received_the_recommendation_for_its_oral_treatment_Oriahnn_to_treat_heavy_menstrual_bleeding_due_to_uterine_fibroids\"><\/span><strong>AbbVie has received the recommendation for its oral treatment Oriahnn to treat heavy menstrual bleeding due to uterine fibroids.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft is-resized\"><img decoding=\"async\" src=\"https:\/\/lh6.googleusercontent.com\/fHdBcEPusIKDFbjyrklX4a-yDrmWaobadR0b7QItFX3LzgMyfKHW2CJG-JgUDfWaJWsuxnFRmXYYWRjyZ2_Pt_RZ5xOdZY_LNgWzfTQekeBt5xQtqZDrDEus51pjSCmCZrUnuuAoRk-RdWJzCQ\" alt=\"abbvie\" width=\"145\" height=\"76\"\/><\/figure><\/div>\n\n\n<p><strong><\/strong> In the first-of-kind approval, the company has won the approval for its oral drug, <strong>Oriahnn<\/strong> (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), which has been developed by AbbVie jointly with Neurocrine Biosciences.&nbsp;<\/p>\n\n\n\n<p>The drug, an oral combination of elagolix and E2\/NETA (estradiol\/norethindrone acetate), has been developed to regulate and control heavy menstrual bleeding due to uterine fibroids in premenopausal women. The traditional approach to treat the heavy bleeding involved surgery, which is the leading cause of hysterectomies.<\/p>\n\n\n\n<p>Earlier the duo captured the approval for their elagolix for the treatment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/endometriosis-market\">endometriosis<\/a>-associated pain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-sciences-reported-the-results-of-a-phase-iii-trial-study-evaluating-the-efficacy-and-safety-of-remdesivir-in-moderate-covid-19-patients\"><span class=\"ez-toc-section\" id=\"Gilead_Sciences_reported_the_results_of_a_Phase_III_trial_study_evaluating_the_efficacy_and_safety_of_Remdesivir_in_moderate_COVID-19_patients\"><\/span><strong>Gilead Sciences reported the results of a Phase III trial study evaluating the efficacy and safety of Remdesivir in moderate COVID-19 patients.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-gallery alignleft has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"311\" height=\"162\" data-id=\"9465\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02160517\/gilead.png\" alt=\"\" class=\"wp-image-9465\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02160517\/gilead.png 311w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02160517\/gilead-300x156.png 300w\" sizes=\"(max-width: 311px) 100vw, 311px\" \/><\/figure>\n<\/figure>\n\n\n\n<p>The company revealed the results after 5-day and 10-day courses of treatment with the antiviral drug plus standard-of-care, and the results were positive against standard-of-care alone.&nbsp;<\/p>\n\n\n\n<p>In a 5-day course, patients were 65% more likely to see clinical improvement at 11 days compared to those treated with standard-of-care only. Whereas, on Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, achieving statistical significance.<\/p>\n\n\n\n<p>According to the company, three randomized clinical trials with remdesivir in <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a> are there, and the trials demonstrated remdesivir\u2019s<strong> <\/strong>improved clinical outcomes by several different measures.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-russia-s-ministry-of-health-gave-an-emergency-use-approval-for-avifavir-to-fight-sars-cov-2-infections\"><span class=\"ez-toc-section\" id=\"Russias_Ministry_of_Health_gave_an_emergency_use_approval_for_Avifavir_to_fight_SARS-CoV-2_infections\"><\/span><strong>Russia\u2019s Ministry of Health gave an emergency use approval for Avifavir to fight SARS-CoV-2 infections.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft is-resized\"><img decoding=\"async\" src=\"https:\/\/lh3.googleusercontent.com\/ukpGfYvOP5cset8dhdjA-ErkEFQdT3RuxBcKbEr7dnxE4PKv1heI3rTQfGwTeFZvO6A62juuglXOM6gJ4oXzHyfnBa4cjz4vBLKE5WmQSc2lOfvar7XUWMiLV7AOEf8H-SccT2MBGejq4kX4Cg\" alt=\"Russian Direct Investment Fund\" width=\"125\" height=\"67\"\/><\/figure><\/div>\n\n\n<p>Originally manufactured to fight severe forms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/influenza-a-infections-market\">influenza<\/a>, Avifavir under clinical trials showed efficacy and safety in disrupting the reproductive mechanisms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID-19<\/strong><\/a>.&nbsp;<\/p>\n\n\n\n<p>The drug has already been approved for <a href=\"https:\/\/www.delveinsight.com\/report-store\/influenza-a-infections-pipeline-insight\">influenza <\/a>in Japan in 2014, so its safety is well established and studied and recently the Russian health authority has given the green signal to antiviral drug Avifavir against coronavirus, and is set to proceed for wider clinical trials in up to 330 <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\"><strong>COVID-19<\/strong><\/a> patients in Russia.&nbsp;<\/p>\n\n\n\n<p>Now, the Russian Direct Investment Fund (RDIF), Russia&#8217;s sovereign wealth fund, and the ChemRar Group are geared up to deliver 60,000 courses of Avifavir to Russian hospitals in June.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate &#8211; LY-CoV555.&nbsp; LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people globally.&nbsp; The antibody was developed by Lilly after [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9470,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":3,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1167,169,1155,204,1207,1216,985,1212,1210,1211,1215,1203,381,1214,1209,1202,1204,1196,1205,1208,17603,1206],"industry":[17225],"therapeutic_areas":[17231,17243],"class_list":["post-9458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-business-consultants","tag-clinical-trials","tag-consultancy","tag-delveinsight","tag-drosophila-melanogaster","tag-emerging-therapeutics","tag-glaxosmithkline","tag-hemispherex","tag-idera-pharmaceuticals","tag-immune-design","tag-index-therapeutics","tag-industry-reports","tag-market-research","tag-mologen","tag-novimmune","tag-pharam-consultant","tag-pharma-reports","tag-pharma-research","tag-pharmaceutical-reports","tag-tlr1-tlr10","tag-toll-like-receptor-modulatorsampligen","tag-toll-like-receptors","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Eli Lilly, AbCellera, Gilead, AbbVie, RDIF<\/title>\n<meta name=\"description\" content=\"Eli Lilly\u2019s COVID-19 Antibody trial; Approval for Oriahnn; Gilead\u2019s Remdesivir trial; Russia approves Avifavir to treat Covid-19\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Eli Lilly, AbCellera, Gilead, AbbVie, RDIF\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly\u2019s COVID-19 Antibody trial; Approval for Oriahnn; Gilead\u2019s Remdesivir trial; Russia approves Avifavir to treat Covid-19\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-02T12:25:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:16:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Eli Lilly, AbCellera, Gilead, AbbVie, RDIF","description":"Eli Lilly\u2019s COVID-19 Antibody trial; Approval for Oriahnn; Gilead\u2019s Remdesivir trial; Russia approves Avifavir to treat Covid-19","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Eli Lilly, AbCellera, Gilead, AbbVie, RDIF","og_description":"Eli Lilly\u2019s COVID-19 Antibody trial; Approval for Oriahnn; Gilead\u2019s Remdesivir trial; Russia approves Avifavir to treat Covid-19","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-02T12:25:48+00:00","article_modified_time":"2023-02-10T06:16:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead","name":"Pharma News | Eli Lilly, AbCellera, Gilead, AbbVie, RDIF","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news.jpg","datePublished":"2020-06-02T12:25:48+00:00","dateModified":"2023-02-10T06:16:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Eli Lilly\u2019s COVID-19 Antibody trial; Approval for Oriahnn; Gilead\u2019s Remdesivir trial; Russia approves Avifavir to treat Covid-19","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/02175518\/news-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business consultants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Drosophila melanogaster<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Emerging therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemispherex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idera Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immune Design<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">InDex Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">industry reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mologen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharam consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TLR1-TLR10<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toll Like Receptor ModulatorsAmpligen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toll-like receptors<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business consultants<\/span>","<span class=\"advgb-post-tax-term\">Clinical trials<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Drosophila melanogaster<\/span>","<span class=\"advgb-post-tax-term\">Emerging therapeutics<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Hemispherex<\/span>","<span class=\"advgb-post-tax-term\">Idera Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Immune Design<\/span>","<span class=\"advgb-post-tax-term\">InDex Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">industry reports<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Mologen<\/span>","<span class=\"advgb-post-tax-term\">Novimmune<\/span>","<span class=\"advgb-post-tax-term\">pharam consultant<\/span>","<span class=\"advgb-post-tax-term\">pharma reports<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical reports<\/span>","<span class=\"advgb-post-tax-term\">TLR1-TLR10<\/span>","<span class=\"advgb-post-tax-term\">Toll Like Receptor ModulatorsAmpligen<\/span>","<span class=\"advgb-post-tax-term\">Toll-like receptors<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 2, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Jun 2, 2020 5:55 pm","modified":"Updated on Feb 10, 2023 11:46 am"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9458"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9458\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9470"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9458"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9458"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}